Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for the year 2024. For the period, the company expects net revenue to be between $360 million and $380 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.08 USD | +3.61% | +12.30% | +14.48% |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
Apr. 23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.48% | 1.42B | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024